|Day Low/High||213.18 / 220.00|
|52 Wk Low/High||95.58 / 220.01|
Some of the best opportunities are in lesser-known niche markets such as medical devices and services.
The contract research company's shares will not stay in a tight trading range indefinitely, so would-be buyers should be prepared to act.
CRL could weaken further in upcoming weeks for a better buying opportunity.
CRL looks strong and probably capable of further gains but in the short-run we could see a pullback.
Argus Research details 24 stocks likely to be impacted, one way or the other, by trade wars and tariffs.
But we could see more volatility in the market.
It’s not easy for value investors to gain exposure to the growth-fueled and often-pricey biotech sector.
There is building consensus around a September rate hike.
Hospitals, biotechs and drug makers continue to hold their own.
Many of these firms are pouring money into share buybacks -- instead of their long-term pipelines.